NCT06798363 Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
| NCT ID | NCT06798363 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | West China Hospital |
| Condition | Infantile Hemangioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 32 participants in total. It began in 2025-01-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
Eligibility Criteria
Inclusion Criteria: 1. all patients with ulcer IH; 2. children with ulcer IH treated with propranolol. Exclusion Criteria: 1\) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons. \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06798363 clinical trial?
This trial is open to participants of all sexes, up to 1 Year, studying Infantile Hemangioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06798363 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06798363 currently recruiting?
Yes, NCT06798363 is actively recruiting participants. Contact the research team at jijiyuanyuan@163.com for enrollment information.
Where is the NCT06798363 trial being conducted?
This trial is being conducted at Chengdu, China, Chengdu, China, Chengdu, China.
Who is sponsoring the NCT06798363 clinical trial?
NCT06798363 is sponsored by West China Hospital. The trial plans to enroll 32 participants.